Radcliffe Capital Management L.P. Purchases New Shares in Drugs Made In America Acquisition II Corp. $DMII

Radcliffe Capital Management L.P. acquired a new position in Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 575,607 shares of the company’s stock, valued at approximately $5,699,000.

Other institutional investors have also recently bought and sold shares of the company. Deltec Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the fourth quarter worth approximately $495,000. Wolverine Asset Management LLC acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth $10,521,000. ABC Arbitrage SA acquired a new stake in shares of Drugs Made In America Acquisition II during the 4th quarter worth $396,000. Wealthspring Capital LLC bought a new position in shares of Drugs Made In America Acquisition II in the fourth quarter worth $4,049,000. Finally, HighTower Advisors LLC acquired a new position in Drugs Made In America Acquisition II in the fourth quarter valued at about $7,817,000.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on DMII shares. Weiss Ratings upgraded shares of Drugs Made In America Acquisition II from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Wall Street Zen raised shares of Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Drugs Made In America Acquisition II Stock Performance

DMII opened at $10.09 on Wednesday. The firm has a 50 day moving average of $10.04. Drugs Made In America Acquisition II Corp. has a 1-year low of $9.86 and a 1-year high of $10.09.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.